

Cory A Dunnick

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11359023/publications.pdf>

Version: 2024-02-01

61
papers

1,654
citations

304743

22
h-index

315739

38
g-index

62
all docs

62
docs citations

62
times ranked

2068
citing authors

#	ARTICLE	IF	CITATIONS
1	The epidemiology of acne vulgaris in late adolescence. <i>Adolescent Health, Medicine and Therapeutics</i> , 2016, 7, 13.	0.9	183
2	Hand hygiene during COVID-19: Recommendations from the American Contact Dermatitis Society. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 1730-1737.	1.2	160
3	Acne Vulgaris: Pathogenesis, Treatment, and Needs Assessment. <i>Dermatologic Clinics</i> , 2012, 30, 99-106.	1.7	94
4	A systematic review of satisfaction with teledermatology. <i>Journal of Telemedicine and Telecare</i> , 2018, 24, 263-270.	2.7	92
5	Social Networking Sites. <i>JAMA Dermatology</i> , 2014, 150, 56.	4.1	89
6	Leprosy: Clinical aspects and diagnostic techniques. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 1-14.	1.2	83
7	Occupational dermatitis to facial personal protective equipment in health care workers: A systematic review. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 486-494.	1.2	81
8	Effectiveness of Online vs In-Person Care for Adults With Psoriasis. <i>JAMA Network Open</i> , 2018, 1, e183062.	5.9	73
9	American Contact Dermatitis Society Core Allergen Series: 2017 Update. <i>Dermatitis</i> , 2017, 28, 141-143.	1.6	65
10	The role of cannabinoids in dermatology. <i>Journal of the American Academy of Dermatology</i> , 2017, 77, 188-190.	1.2	54
11	Leprosy: Treatment and management of complications. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 17-30.	1.2	50
12	Pediatric Contact Dermatitis Registry Inaugural Case Data. <i>Dermatitis</i> , 2016, 27, 293-302.	1.6	49
13	American Contact Dermatitis Society Core Allergen Series. <i>Dermatitis</i> , 2013, 24, 7-9.	1.6	48
14	Recent trends in disease severity and quality of life instruments for patients with atopic dermatitis: A systematic review. <i>Journal of the American Academy of Dermatology</i> , 2016, 75, 906-917.	1.2	45
15	Prevention of Nickel Allergy: The Case for Regulation?. <i>Dermatologic Clinics</i> , 2009, 27, 155-161.	1.7	43
16	American Contact Dermatitis Society Core Allergen Series: 2020 Update. <i>Dermatitis</i> , 2020, 31, 279-282.	1.6	40
17	Online Care Versus In-Person Care for Improving Quality of Life in Psoriasis: A Randomized Controlled Equivalency Trial. <i>Journal of Investigative Dermatology</i> , 2019, 139, 1037-1044.	0.7	37
18	The Burden of Skin and Subcutaneous Diseases in the United States From 1990 to 2017. <i>JAMA Dermatology</i> , 2020, 156, 874.	4.1	36

#	ARTICLE	IF	CITATIONS
19	Janus kinase inhibition in Down syndrome: 2 cases of therapeutic benefit for alopecia areata. JAAD Case Reports, 2019, 5, 365-367.	0.8	33
20	Comparing cutaneous research funded by the US National Institutes of Health (NIH) with the US skin disease burden. Journal of the American Academy of Dermatology, 2015, 73, 383-391.e1.	1.2	30
21	Access to Dermatological Care with an Innovative Online Model for Psoriasis Management: Results from a Randomized Controlled Trial. Telemedicine Journal and E-Health, 2019, 25, 619-627.	2.8	26
22	Comparing Cutaneous Research Funded by the National Institute of Arthritis and Musculoskeletal and Skin Diseases with 2010 Global Burden of Disease Results. PLoS ONE, 2014, 9, e102122.	2.5	25
23	The most cited articles and authors in dermatology: A bibliometric analysis of 1974-2019. Journal of the American Academy of Dermatology, 2020, 83, 201-205.	1.2	24
24	Global mortality from conditions with skin manifestations. Journal of the American Academy of Dermatology, 2014, 71, 1137-1143.e17.	1.2	23
25	American Contact Dermatitis Society Allergens of the Year 2000 to 2020. Dermatologic Clinics, 2020, 38, 309-320.	1.7	13
26	The History of Surfactants and Review of Their Allergic and Irritant Properties. Dermatitis, 2021, 32, 289-297.	1.6	13
27	Oral tofacitinib for the treatment of alopecia areata in pediatric patients. Pediatric Dermatology, 2022, 39, 31-34.	0.9	13
28	Primary and Secondary Chemoprevention of Malignant Melanoma. American Journal of Clinical Dermatology, 2016, 17, 625-634.	6.7	12
29	A Review of the Current Evidence Connecting Seborrheic Dermatitis and Parkinson's Disease and the Potential Role of Oral Cannabinoids. Dermatology, 2021, 237, 872-877.	2.1	10
30	Pediatric melanoma: Characterizing 256 cases from the Colorado Central Cancer Registry. Pediatric Dermatology, 2019, 36, 219-222.	0.9	9
31	Triclosan and Its Alternatives in Antibacterial Soaps. Dermatitis, 2019, 30, 352-357.	1.6	9
32	Age-related differences in patch testing results among children: Analysis of North American Contact Dermatitis Group Data, 2001-2018. Journal of the American Academy of Dermatology, 2022, 86, 818-826.	1.2	7
33	Minimal improvements in the global burden of skin disease from 1990 to 2013. Journal of the American Academy of Dermatology, 2017, 76, 148-149.e2.	1.2	6
34	Genetic Risk Factors for Development of Atopic Dermatitis: a Systematic Review. Current Dermatology Reports, 2017, 6, 297-308.	2.1	6
35	Patch testing with ammonium persulfate: The North American Contact Dermatitis Group Experience, 2015-2018. Journal of the American Academy of Dermatology, 2022, 87, 1014-1023.	1.2	6
36	Occupational Contact Dermatitis in Dental Personnel: A Retrospective Analysis of the North American Contact Dermatitis Group Data, 2001 to 2018. Dermatitis, 2022, 33, 80-90.	1.6	6

#	ARTICLE	IF	CITATIONS
37	Disease Severity and Quality of Life Measurements in Contact Dermatitis: A Systematic Review 2005–2015. <i>Dermatitis</i> , 2016, 27, 362-371.	1.6	5
38	National trends in free public sunscreen dispensers. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 1109-1111.	1.2	5
39	Importance of Supplemental Patch Testing Beyond a Screening Series for Patients With Dermatitis. <i>JAMA Dermatology</i> , 2021, 157, 1456.	4.1	5
40	Chlorpromazine-induced skin pigmentation with corneal and lens opacities. <i>Cutis</i> , 2014, 93, 247-50.	0.3	5
41	Patch Test Practice Patterns of Members of the American Contact Dermatitis Society. <i>Dermatitis</i> , 2020, 31, 272-275.	1.6	4
42	Patch testing with glucosides: The North American Contact Dermatitis Group experience, 2009-2018. <i>Journal of the American Academy of Dermatology</i> , 2022, 87, 1033-1041.	1.2	4
43	Chemoprevention of Keratinocyte Carcinomas: An Updated Review. <i>American Journal of Clinical Dermatology</i> , 2016, 17, 475-484.	6.7	3
44	Environmental Risk Factors for Development of Atopic Dermatitis: a Systematic Review. <i>Current Dermatology Reports</i> , 2017, 6, 169-177.	2.1	3
45	Complementary and Alternative Methods for Treatment of Acne Vulgaris: a Systematic Review. <i>Current Dermatology Reports</i> , 2018, 7, 359-370.	2.1	3
46	Analysis of conflicts of interest in pharmaceutical payments made to Food and Drug Administration physician advisers after dermatologic drug approval. <i>Journal of the American Academy of Dermatology</i> , 2019, 81, 1419-1420.	1.2	3
47	Spray sunscreen: Characterizing application area density and implications for sun protection. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 749-751.	1.2	3
48	Prevalence and trend of allergen sensitization in patients referred for patch testing with a final diagnosis of psoriasis: North American Contact Dermatitis Group data, 2001–2016. <i>Contact Dermatitis</i> , 2021, 85, 435-445.	1.4	3
49	Comparison of Contact Allergens in Bar Soaps and Liquid Body Washes. <i>Dermatitis</i> , 2018, 29, 51-53.	1.6	2
50	Patients with patch test reactions associated with eye care products: Retrospective analysis of North American contact dermatitis group data, 2001–2018. <i>Contact Dermatitis</i> , 2021, 85, 712-715.	1.4	2
51	Patch Test Reactions Associated With Topical Medications: A Retrospective Analysis of the North American Contact Dermatitis Group Data (2001–2018). <i>Dermatitis</i> , 2022, 33, 144-154.	1.6	2
52	The Contact Dermatitis Quality of Life Index (CDQL): Survey Development and Content Validity Assessment. <i>JMIR Dermatology</i> , 2021, 4, e30620.	0.7	2
53	Lanolin Allergic Reactions: North American Contact Dermatitis Group Experience, 2001 to 2018. <i>Dermatitis</i> , 2022, Publish Ahead of Print, .	1.6	2
54	American Contact Dermatitis Society. <i>Dermatitis</i> , 2014, 25, 39.	1.6	1

#	ARTICLE	IF	CITATIONS
55	Evaluating dermatology curricula in US medical schools. Journal of the American Academy of Dermatology, 2021, 85, 513-514.	1.2	1
56	Dermatology Residency Research Policies: A 2021 National Survey. International Journal of Women's Dermatology, 2021, 7, 787-792.	2.0	1
57	Evaluating medical student assessment of common dermatologic conditions across Fitzpatrick phototypes and skin of color. Journal of the American Academy of Dermatology, 2021, , .	1.2	1
58	Wilderness dermatology: mountain exposures. Dermatology Online Journal, 2017, 23, .	0.5	1
59	A hyperpigmented rash on face and chest. International Journal of Dermatology, 2018, 57, 791-793.	1.0	0
60	Contact dermatitis in music professionals referred for patch testing: North <scp>American</scp> Contact Dermatitis Group data, 1996â€“2018. Contact Dermatitis, 2021, 85, 359-362.	1.4	0
61	Prevalence and Trend of Allergen Sensitization in Patients with a Diagnosis of Seborrheic Dermatitis After Patch Testing, North American Contact Dermatitis Group Data, 2001-2016. Journal of the American Academy of Dermatology, 2021, , .	1.2	0